Physician profile
Jason Chan
NPI 1497593727
$4,715.05
in general payments reported to CMS, 2019-2025
15 companies · $3,470 in 2025
The $3,470 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,245 · 2025: $3,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,530 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,529.59 |
| Education | $185.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,035.82 | 2024-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $661.23 | 2024-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $600.17 | 2025 | Adbry, Anzupgo |
| Genzyme Corporation | $390.68 | 2024-2025 | |
| Incyte Corporation | $366.85 | 2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $323.44 | 2024-2025 | Nemluvio |
| Botanix Sb INC | $199.64 | 2025 | Sofdra |
| Abbvie INC. | $196.90 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $190.49 | 2025 | Cabtreo |
| Arcutis Biotherapeutics, INC. | $187.40 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $184.63 | 2024-2025 | |
| Janssen Biotech, INC. | $143.08 | 2024-2025 | Tremfya |
| Ucb, INC. | $105.04 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $83.24 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $46.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.